Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study
NCT ID: NCT01292369
Last Updated: 2011-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
560 participants
OBSERVATIONAL
2011-02-28
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-invasive Detection of Breast Cancer by Breath Analysis
NCT06499077
Breath Gas Analysis for the Diagnosis of Breast Cancer
NCT01105468
Non Invasive Detection of Lung and Breast Cancer by Odor Signature
NCT02195076
Identifying Patterns in the Breath of Individuals With Breast Cancer
NCT06512350
A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer
NCT02888366
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the Technion labs, a new system for breath samples diagnosis, is being developed. The system is based on Nanoparticles technology.
The current study will try to identify colon and breast cancer patients through their breath samples and discriminate them from healthy individuals.
Men and women coming for colonoscopy or breast biopsy will be recruited for the study. Breath samples will be taken from all volunteers before the medical test. Subjects with positive cancer results by biopsy will be the test groups for both diseases, all others will be the control.
The research goal is to test the NaNose system ability to discriminate between healthy and sick.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast cancer
Women diagnosed with breast cancer by a positive biopsy test after mammography.
No interventions assigned to this group
Breast control
Women with negative biopsy result done due to a suspicious mammography exam.
No interventions assigned to this group
Colon cancer
Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.
No interventions assigned to this group
Colon control
Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspicious finding on breast imaging requiring a biopsy.
* Complaints indicating the possibility of colon cancer: Blood in stool, weight loss, constipation, anemia, family history of colon cancer.
Exclusion Criteria
* History of malignant disease and treatments.
50 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technion, Israel Institute of Technology
OTHER
Rambam Health Care Campus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AMIT- Alfred Mann institute in the technion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RAMBAM medical center
Haifa, , Israel
Carmel medical center
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RMB-0566.CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.